SEARCH

SEARCH BY CITATION

References

  • 1
    Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 47887.
  • 2
    Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2011; 35: 64762.
  • 3
    Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 4018.
  • 4
    Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. The Lancet 2013; 381: 21007.
  • 5
    Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 187887.
  • 6
    Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195206.
  • 7
    Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once daily simeprevir (TMC435) with peginterferon / ribavirin for treatment naive hepatitis C genotype 1 infected patients in Japan: the DRAGON study. J Gastroenterol 2014; 49: 13847.
  • 8
    Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 191829.
  • 9
    Jacobson I, Dore G, Foster G, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment naive patients: results from QUEST-1, a Phase III Trial. J Hepatol 2013; 58(Supplement 1): S574.
  • 10
    Manns M, Marcellin P, Poordad F, et al. Simeprevir with Peginterferon alpha 2a or alpha 2b and ribavirin in treatment naive HCV genotype 1 patients: QUEST-2, a randomized Phase III trial. J Hepatol 2013; 58(Supplement 1): S568.
  • 11
    Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 214354.
  • 12
    Jensen D, Asselah T, Dieterich D, Foster G. A Pooled Analysis of Two Randomized, Double Blind Placebo Controlled Phase III Trials (STARTVerso 1&2) of Faldaprevir Plus Pegylated Interferonalfa 2a and Ribavirin in Treatment Naive Patients With Chronic Hepatits C Genotype 1 Infection. Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Washington DC, 2013; 1088.
  • 13
    Lawitz E, Forns X, Zeuzum S, et al. Simeprevir With Peginterferon / Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon Based Therapy: Results From PROMISE, a Phase III Trial. Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Washington DC, 2013; 1092.
  • 14
    Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 43041.e6.
  • 15
    Jacobson I, Ghalib R, Rodriguez-Torres M, et al. SVR Results of a Once-Daily Regimen of Simeprevir (TMC435) Plus Sofosbuvir (GS-7977) With or Without Ribavirin in Cirrhotic and non-Cirrhotic HCV Genotype 1 Treatment Naive and Prior Null Repsonder Patients: The COSMOS Study. Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Washington DC, 2013; LB3.
  • 16
    Sulkowski MS, Bourlière M, Bronowicki J-P, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57: 215563.
  • 17
    Jacobson I, Asselah T, Perenci P, Foster G. STARTVerso 3: A Randomized, Double Blind Placebo Controlled Phase III Trial of Faldaprevir in Combination With Pegylated Interferon Alfa 2a and Ribavirin in Treatment Experienced Patients With Chronic Hepatitis C Genotype 1 Infection. Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Washington DC, 2013; 1100.
  • 18
    Osinusi A, Meissner EG, Lee Y, et al. Sofosbuvir and ribavirin for hepatitis c genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 80411.
  • 19
    Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 weeks versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 5539.
  • 20
    Zeuzem S, Dusheiko G, Salupere R, et al. Sofosbuvir and Ribavirin for 12 or 24 Weeks for Patients With HCV Genotype 2 or 3: The VALENCE Trial. Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Washington DC, 2013; 1085.
  • 21
    Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 186777.
  • 22
    Hadziyannis SJ, Sette JH, Morgan TR, et al. Peginterferon-Π± 2a and Ribavirin combination therapy in chronic hepatitis CA randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 23
    Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 9939.
  • 24
    Lawitz E, Poordad F, Brainard D. Sofosbuvir in Combination With PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment Experienced Patients With and Without Compensated Cirrhosis: Results From the LONESTAR-2 Study. Annual Meeting of the American Association for the Study of LIver Disease (AASLD), Washington DC, 2013; LB4.
  • 25
    Foster G, Shoeb D, Weatherall A, et al. Randomized controlled trial of 24 and 48 weeks of pegylated interferon alfa 2A plus ribavirin with genotype 3 HCV and cirrhosis. J Hepatol 2013; 58(Supplement): S335.
  • 26
    Moreno C, Hezode C, Marcellin P. Simeprevir with peginterferon/ribavirin in treatment-naive or experienced patients with chronic HCV 4 infection: interim results of a phase III trial. European Aids Conference, Brussels, Belgium, 2013; LBPS9/6.
  • 27
    Rockstroh JBS. Managing HIV / hepatitis C con-infection in the era of direct acting antivirals. BMC Med 2013; 11: 234.
  • 28
    Lacombe KVN, Stitou H. Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1 coinfected patients failing previous antihepatitis C virus therapy: 24-week results. AIDS 2013; 15: 13569.
  • 29
    Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIVA randomized trial. Ann Intern Med 2013; 159: 8696.
  • 30
    Fierer DS, Dieterich DT, Mullen MP, et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis 2014; 58: 8739.
  • 31
    Sulkowski M, Rodriquez-Torres M, Lalezari J. All Oral Therapy With Sofosbuvir Plus Ribavirin for the Treatment of HCV Genotype 1,2 and 3 Infection in Patients Coinfected With HIV (PHOTON-1). Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Washington DC, 2013; 212.
  • 32
    Chastain C, Naggie S. Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014. Current HIV/AIDS Report 2013; 10: 40819.
  • 33
    Rockstroh J, Nelson M, Soriano V, et al. STARTVerso 4 Phase III Trial of Faldaprevir Plus peg Interferon Alfa-2a and Ribavirin (PR) in Patients With HIV and HCV Genotype 1 co-Infection: End of Treatment Repsonse. Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Washington DC, 2013; 1099.
  • 34
    Joshi D, Carey I, Agarwal K. Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. Aliment Pharmacol Ther 2013; 37: 65971.
  • 35
    Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents — A potentially lethal cocktail. Hepatology 2011; 54: 35.
  • 36
    Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 7886.
  • 37
    Curry MPFX, Chung RT. Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection After Liver Transplantation. AASLD, Washington DC, 2013; poster 1091.
  • 38
    Charlton M, Gane E, Manns M. Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After Liver Transplant: Preliminary Results of a Prospective Multicentre Study. Annual Meeting of the American Association for the Study of Liver Disease (AASLD), Washington DC, 2013; LB2.
  • 39
    Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3 – the new treatment challenge. Aliment Pharmacol Ther 2014; 39: 68698.